Xenon Pharmaceuticals (XENE) Other Non Operating Income (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Other Non Operating Income of $548000.0 for Q1 2026, up 1465.71% year-over-year from $35000.0 in Q1 2025, and up 285.14% on a QoQ basis from -$296000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) has 14 years of Other Non Operating Income data on file, last reported at $548000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 1465.71% year-over-year to $548000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 255.6% YoY) and the FY2025 annual result came in at $1.3 million, up 226.69% from the prior year.
- Other Non Operating Income rose to $548000.0 in Q1 2026 per XENE's latest filing, from -$296000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.7 million in Q2 2025 and bottomed at -$2.4 million in Q3 2022.
- The 5-year median for Other Non Operating Income is $35000.0 (2025), against an average of -$50588.2.
- The widest annual swing landed in 2022, when Other Non Operating Income tumbled 1760.16%; it then surged 16880.0% in 2025.
- Tracing XENE's Other Non Operating Income over 5 years: stood at $602000.0 in 2022, then sank by 114.95% to -$90000.0 in 2023, then plunged by 1542.22% to -$1.5 million in 2024, then soared by 79.97% to -$296000.0 in 2025, then soared by 285.14% to $548000.0 in 2026.
- Per Business Quant, the three latest XENE Other Non Operating Income figures stand at $548000.0 (Q1 2026), -$296000.0 (Q4 2025), and -$89000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Xenon Pharmaceuticals | 4.78 Bn | 4.78 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 548,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Sep 30, 2025 | -89,000.00 |
| Jun 30, 2025 | 1.70 Mn |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | -1.48 Mn |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 167,000.00 |
| Dec 31, 2023 | -90,000.00 |
| Sep 30, 2023 | -407,000.00 |
| Jun 30, 2023 | 383,000.00 |
| Mar 31, 2023 | 313,000.00 |
| Dec 31, 2022 | 602,000.00 |
| Sep 30, 2022 | -2.38 Mn |
| Jun 30, 2022 | -411,000.00 |
| Mar 31, 2022 | 299,000.00 |
| Dec 31, 2021 | 214,000.00 |
| Sep 30, 2021 | -128,000.00 |
| Jun 30, 2021 | 117,000.00 |
| Mar 31, 2021 | 155,000.00 |
| Dec 31, 2020 | -1.89 Mn |
| Sep 30, 2020 | 475,000.00 |
| Jun 30, 2020 | 662,000.00 |
| Mar 31, 2020 | -238,000.00 |
| Dec 31, 2019 | 292,000.00 |
| Sep 30, 2019 | -80,000.00 |
| Jun 30, 2019 | 135,000.00 |
| Mar 31, 2019 | 130,000.00 |
| Dec 31, 2018 | -196,000.00 |
| Sep 30, 2018 | 148,000.00 |
| Jun 30, 2018 | -140,000.00 |
| Mar 31, 2018 | -284,000.00 |
| Dec 31, 2017 | -109,000.00 |
| Sep 30, 2017 | 778,000.00 |
| Jun 30, 2017 | 404,000.00 |
| Mar 31, 2017 | 321,000.00 |
| Dec 31, 2016 | -710,000.00 |
| Sep 30, 2016 | -497,000.00 |
| Jun 30, 2016 | 227,000.00 |
| Mar 31, 2016 | 2.30 Mn |
| Dec 31, 2015 | -1.43 Mn |
| Sep 30, 2015 | -3.14 Mn |
| Jun 30, 2015 | 806,000.00 |
| Mar 31, 2015 | -3.17 Mn |
| Dec 31, 2014 | 1.04 Mn |
| Sep 30, 2014 | 392,000.00 |
| Jun 30, 2014 | -285,000.00 |
| Mar 31, 2014 | 200,000.00 |
| Dec 31, 2013 | 358,000.00 |
| Sep 30, 2013 | -243,000.00 |